SEC FORM 3

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Reents Scott T

(Last)

(First)

(Middle)

1 NORTH WAUKEGA

(Street)

NORTH CHICAGO

60064

(City)

(State)

(Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
06/28/2022

3. Issuer Name and Ticker or Trading Symbol
AbbVie Inc. [ ABBV ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	SVP, Chief Financial Officer

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock, $0.01 par value	809	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Option (Right to buy)	02/16/2018⁽¹⁾	02/15/2028	Common Stock	14,140	$61.36	D
Option (Right to buy)	02/15/2019⁽²⁾	02/14/2028	Common Stock	11,810	$114.36	D
Option (Right to buy)	02/21/2020⁽³⁾	02/20/2029	Common Stock	19,470	$79.02	D
Option (Right to buy)	02/20/2021⁽⁴⁾	02/19/2030	Common Stock	28,641	$93.5	D
Option (Right to buy)	02/18/2022⁽⁵⁾	02/17/2031	Common Stock	15,527	$105.92	D
Option (Right to buy)	02/17/2023⁽⁶⁾	02/16/2032	Common Stock	11,383	$144.54	D

Explanation of Responses:

1. Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable as to 4,714 shares on 2/16/2018, as to 4,713 shares on 2/16/2019 and as to 4,713 shares on 2/16/2020.

2. Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable as to 3,936 shares on 2/15/2019, as to 3,937 shares on 2/15/2020 and as to 3,937 shares on 2/15/2021.

3. Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable as to 6,490 shares on 2/21/2020, as to 6,490 shares on 2/21/2021 and as to 6,490 shares on 2/21/2022.

4. Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable as to 9,547 shares on 2/20/2021, as to 9,547 shares on 2/20/2022 and will become exercisable as to 9,547 shares on 2/20/2023.

5. Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable as to 5,176 shares on 2/18/2022, and will become exercisable as to 5,176 shares on 2/18/2023 and as to 5,175 shares on 2/18/2024.

6. Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option will become exercisable as to 3,794 shares on 2/17/2023, as to 3,794 shares on 2/17/2024 and as to 3,795 shares on 2/17/2025.

	Steven L. Scrogham, attorney-in-fact for Scott T. Reents	07/08/2022
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.